The Tips from Other Journals article “New Guideline for Travel Medicine,” (September 15, 2007, page 878) contained an error in Table 2 on page 883. The dosage for atovaquone/proguanil (Malarone) was incorrectly listed as “250/100 mg every day, beginning one to two days pretravel and continuing until 28 days posttravel.” The correct dosage is “250/100 mg every day, beginning one to two days pretravel and continuing until seven days posttravel.” The online version of this article has been corrected, and the corrected table is reprinted below.
Table 2 Antimalarial Medication Recommendations by Destination
| Destination | Medication | |
|---|---|---|
| Argentina and Paraguay, Central America, Haiti and Dominican Republic, Middle East | Chloroquine (Aralen): 500 mg every week, beginning one week pretravel and continuing until four weeks posttravel | |
| Asia, South America (except Argentina and Paraguay), sub-Saharan Africa | Atovaquone/proguanil (Malarone): 250/100 mg every day, beginning one to two days pretravel and continuing until seven days posttravel | |
| or | ||
| Mefloquine (Lariam): 250 mg every week, beginning one week pretravel and continuing until four weeks posttravel* | ||
note:Risk (including drug-resistant strains) may be restricted to regions of some countries; targeted recommendations are available at http://www.cdc.gov/travel.
*— Mefloquine is not recommended for travelers to western Cambodia and forested areas of Thailand-Cambodia and Thailand-Burma borders because of multidrug-resistant Plasmodium falciparum.
